These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25810012)

  • 21. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
    Rugo HS; Seneviratne L; Beck JT; Glaspy JA; Peguero JA; Pluard TJ; Dhillon N; Hwang LC; Nangia C; Mayer IA; Meiller TF; Chambers MS; Sweetman RW; Sabo JR; Litton JK
    Lancet Oncol; 2017 May; 18(5):654-662. PubMed ID: 28314691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
    Burris HA; Lebrun F; Rugo HS; Beck JT; Piccart M; Neven P; Baselga J; Petrakova K; Hortobagyi GN; Komorowski A; Chouinard E; Young R; Gnant M; Pritchard KI; Bennett L; Ricci JF; Bauly H; Taran T; Sahmoud T; Noguchi S
    Cancer; 2013 May; 119(10):1908-15. PubMed ID: 23504821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [BOLERO -- another remarkable step in treatment of breast cancer].
    Rubovszky G; Láng I
    Magy Onkol; 2014 Jun; 58(2):128-32. PubMed ID: 25010761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
    Yam C; Esteva FJ; Patel MM; Raghavendra AS; Ueno NT; Moulder SL; Hess KR; Shroff GS; Hodge S; Koenig KH; Chavez Mac Gregor M; Griner RL; Yeung SJ; Hortobagyi GN; Valero V
    Invest New Drugs; 2019 Apr; 37(2):345-351. PubMed ID: 30610588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Everolimus plus exemestane in postmenopausal patients with estrogen-receptor-positive advanced breast cancer - Japanese subgroup analysis of BOLERO -2].
    Ito Y; Masuda N; Iwata H; Mukai H; Horiguchi J; Tokuda Y; Kuroi K; Mori A; Ohno N; Noguchi S
    Gan To Kagaku Ryoho; 2015 Jan; 42(1):67-75. PubMed ID: 25596682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).
    Jerusalem G; Mariani G; Ciruelos EM; Martin M; Tjan-Heijnen VC; Neven P; Gavila JG; Michelotti A; Montemurro F; Generali D; Simoncini E; Lang I; Mardiak J; Naume B; Camozzi M; Lorizzo K; Bianchetti S; Conte P
    Ann Oncol; 2016 Sep; 27(9):1719-25. PubMed ID: 27358383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer.
    Gombos A; Barthélémy P; Awada A
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):823-34. PubMed ID: 25659402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.
    Toi M; Shao Z; Hurvitz S; Tseng LM; Zhang Q; Shen K; Liu D; Feng J; Xu B; Wang X; Lee KS; Ng TY; Ridolfi A; Noel-Baron F; Ringeisen F; Jiang Z
    Breast Cancer Res; 2017 Apr; 19(1):47. PubMed ID: 28399902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR
    Bardia A; Hurvitz SA; DeMichele A; Clark AS; Zelnak A; Yardley DA; Karuturi M; Sanft T; Blau S; Hart L; Ma C; Rugo HS; Purkayastha D; Moulder S
    Clin Cancer Res; 2021 Aug; 27(15):4177-4185. PubMed ID: 33722897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.
    Beck JT; Hortobagyi GN; Campone M; Lebrun F; Deleu I; Rugo HS; Pistilli B; Masuda N; Hart L; Melichar B; Dakhil S; Geberth M; Nunzi M; Heng DY; Brechenmacher T; El-Hashimy M; Douma S; Ringeisen F; Piccart M
    Breast Cancer Res Treat; 2014 Feb; 143(3):459-67. PubMed ID: 24362951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.
    Generali D; Montemurro F; Bordonaro R; Mafodda A; Romito S; Michelotti A; Piovano P; Ionta MT; Bighin C; Sartori D; Frassoldati A; Cazzaniga ME; Riccardi F; Testore F; Vici P; Barone CA; Schirone A; Piacentini F; Nolè F; Molino A; Latini L; Simoncini EL; Roila F; Cognetti F; Nuzzo F; Foglietta J; Minisini AM; Goffredo F; Portera G; Ascione G; Mariani G
    Oncologist; 2017 Jun; 22(6):648-654. PubMed ID: 28432226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy.
    Cook MM; Al Rabadi L; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
    Oncologist; 2021 Feb; 26(2):101-106. PubMed ID: 33230905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.
    Steger GG; Egle D; Bartsch R; Pfeiler G; Petru E; Greil R; Helfgott R; Marth C; Öhler L; Hubalek M; Lang A; Tinchon C; Haslbauer F; Redl A; Hock K; Hennebelle M; Mraz B; Gnant M
    Breast; 2020 Apr; 50():64-70. PubMed ID: 32062536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population.
    Ciruelos E; Jerusalem G; Martin M; Tjan-Heijnen VCG; Neven P; Gavila J; Montemurro F; Generali D; Lang I; Martínez-Serrano MJ; Perelló MF; Conte P
    Clin Transl Oncol; 2020 Oct; 22(10):1857-1866. PubMed ID: 32170637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer.
    Diaby V; Adunlin G; Zeichner SB; Avancha K; Lopes G; Gluck S; Montero AJ
    Breast Cancer Res Treat; 2014 Sep; 147(2):433-41. PubMed ID: 25012857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Everolimus Plus Letrozole for Treatment of Patients With HR
    Safra T; Kaufman B; Kadouri L; Efrat Ben-Baruch N; Ryvo L; Nisenbaum B; Evron E; Yerushalmi R
    Clin Breast Cancer; 2018 Apr; 18(2):e197-e203. PubMed ID: 29097108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer.
    Rugo HS
    Clin Breast Cancer; 2016 Feb; 16(1):18-22. PubMed ID: 26507507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
    Gnant M; Baselga J; Rugo HS; Noguchi S; Burris HA; Piccart M; Hortobagyi GN; Eakle J; Mukai H; Iwata H; Geberth M; Hart LL; Hadji P; El-Hashimy M; Rao S; Taran T; Sahmoud T; Lebwohl D; Campone M; Pritchard KI
    J Natl Cancer Inst; 2013 May; 105(9):654-63. PubMed ID: 23425564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The drug of the month: everolimus (Afinitor) for the treatment of metastatic breast cancer].
    Jerusalem G; Rorive A; Collignon J
    Rev Med Liege; 2014 Sep; 69(9):510-7. PubMed ID: 25796760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.